NCT02164058撤回不适用
A Randomized Controlled Multicenter Study on the Use of the TandemHeart to Reduce Infarct Size
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Primary Safety
研究概览
简要总结
The purpose of this study is to determine if a device known as the TandemHeart® System (TandemHeart) can help limit heart damage and reduce serious complications after a certain type of heart attack (acute ST elevation anterior wall myocardial infarction [STEMI]) by evaluating the use of the TandemHeart system prior to a procedure called percutaneous coronary intervention (PCI)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Primary Safety
时间窗: 30 days post-procedure
Major Adverse Cardiac or Cerebrovascular Events (MACCE): * Death, all cause * Stroke * Reinfarction * Major vascular complications
次要结局
未报告次要终点
研究者
相似试验
终止
不适用
Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart TransplantationCardiac FailureHeart FailureHeart Failure, Left-sidedCongestive Heart FailureNCT02205411ReliantHeart Inc.17
尚未招募
不适用
Cardiac Autonomic Nerve Improvement and Pacemaker Therapy in Patients With Sinus BradycardiaSinus BradycardiaNCT05021627Shanghai Chest Hospital240
已完成
不适用
Teaching Inhaler Use With the INCA Device in a Community Pharmacy SettingPulmonary Disease, Chronic ObstructiveAsthmaNCT02203266Beaumont Hospital152
Unknown
不适用
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical StudyAntineoplastic AgentsCoronary Artery DiseaseNCT03284255Shanghai Bio-heart Biological Technology Co., Ltd.431
已完成
3 期
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)Diabetes Mellitus, Type 2NCT00087516Merck Sharp & Dohme LLC741